Symbiotec Pharmalab Limited (formerly Symbiotec Pharmalab Private Limited) was incorporated on September 20, 2002, in Madhya Pradesh, and its name was changed to Symbiotec Pharmalab Limited with a fresh certificate issued on September 26, 2025. The company manufactures and sells active pharmaceutical ingredients (APIs) and intermediates, with a stated global leadership position in corticosteroid and steroidal-hormone APIs.
Symbiotec is described as one of the few companies globally—and the only Indian manufacturer—having continuous manufacturing for progesterone API. It uses flow chemistry for progesterone production in a new block at its Pithampur facility. The business has over 30 years of industry experience, evolving from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from USFDA, EU-GMP, Korea’s Ministry of Food and Drug Safety, and other global organizations.
Operationally, API production began at the Rau facility in 2004, followed by expanded API and hormone synthesis at Pithampur in 2010. Capacity additions include a 5 KL biotech plant at Pithampur (2012) and a 35 KL fermentation project there. The company has had two operational industrial-scale API manufacturing facilities with maximum chemical synthesis capacity of 584.67 metric tons and fermentation capacity of 300 KL, and it has commissioned two additional facilities, taking total maximum fermentation capacity to 700 KL and adding complex injectables capacity of 20 million vials per annum. It also expanded a sterile plant at Rau in 2022–23, commissioned a complex injectables facility at Mhow, and installed 400 KL capacity at the Ujjain plant in FY2025.
The company has filed a Draft Red Herring Prospectus with SEBI and plans an IPO of Rs 2,180 crore, comprising a fresh issue of Rs 150 crore and an offer for sale of Rs 2,030 crore (face value Rs 2 per share).
